BPC-157 vs Thymosin-β4

The two halves of the most common recovery stack

These two are so often used together that people treat them as one thing. They are not. BPC-157 is a 15-amino-acid fragment from stomach juice; thymosin-β4 is a 43-amino-acid actin-binding protein found in nearly every human cell. The evidence is where they really part company: BPC-157 has no published controlled human trials at all, while thymosin-β4 has reached human trials, though for dry eye, as topical drops, not for the injected musculoskeletal use people actually report. Neither has a human trial supporting the thing they are stacked for.

Human skeletal muscle fibres joining a collagen tendon.

BPC-157 Healing & repair Body Protection Compound 157 Full entry →

Fine actin filaments in a mammalian cell cytoskeleton.

Thymosin-β4 Healing & repair Tβ4, Timbetasin, often sold as TB-500 Full entry →

BPC-157 compared with Thymosin-β4
	BPC-157	Thymosin-β4
Evidence behind it	Animal studies	Human trials
Worth knowing	Essentially all of this is rodent data. There are no published controlled human trials, and claims about joint or gut healing in people are extrapolation.	Dry eye trials showed promise but no approval followed. Sold widely as 'TB-500', often as a different fragment than the full peptide.
Approval	Research only	In trials
Category	Healing & repair	Healing & repair
What it is	A 15-amino-acid synthetic peptide based on a protein fragment found in stomach juice. In animal studies it has been linked to faster healing of tendon, muscle, gut and skin injuries, new blood vessel growth, and effects on nitric oxide signaling.	A 43-amino-acid peptide found in nearly all human cells. It binds actin, the protein cells use to move, which helps repair cells migrate into damaged tissue. Animal studies link it to blood vessel growth, faster wound and corneal healing, and less scarring and inflammation.
How it works	Derived from a protein in gastric juice. Reported to upregulate growth hormone receptors via the phospholipase C pathway and to drive angiogenesis — new blood vessel growth into damaged tissue.	Regulates actin, the protein cells use to move, which lets repair cells migrate into damaged tissue. Frequently stacked with BPC-157 for severe musculoskeletal injury.
What studies report	Faster tendon, ligament and muscle healing in rat injury models Protection of the stomach and gut lining against NSAID and alcohol damage in rodents New blood vessel growth at injury sites in animals	Faster corneal and skin wound healing in animals and early eye trials Reduced scarring and inflammation after heart injury in animals Drives cell migration into damaged tissue
Dosing	Reported, not evidence 250–500 mcg daily, subcutaneous, is the most commonly cited range Often injected near the injury site for tendon and ligament work Run in 4–8 week blocks Oral capsules used instead for gut complaints	From studies Topical eye drops, twice daily — Dry eye phase 2/3 trials. Improved signs and symptoms in some endpoints Reported, not evidence 2–2.5 mg twice weekly as a loading period, then weekly maintenance Routinely paired with BPC-157
Why people take it	Achilles and other tendon tearsACL and meniscus injuryRotator cuff tearsIT band syndromeGut lining, GERD and ulcersTendon, ligament and muscle injury	Severe musculoskeletal injuryTendon and ligament repairReduced scarringOften stacked with BPC-157Tissue repair and recoveryTendon and muscle injury
In practice	Among the most widely used peptides in the injury-recovery community, usually run in 4–8 week blocks Commonly injected near the injury site for tendon and ligament problems, or systemically Oral and capsule forms are preferred for gut complaints, since it originates in the digestive tract Routinely stacked with TB-500 — the pairing is common enough to have its own nickname Sold pre-blended with thymosin-β4 as a “Wolverine stack”, and in four-way GHK and KPV blends, so buyers often take several peptides without measuring any of them separately	Usually run as a loading period followed by less frequent maintenance The standard partner to BPC-157 for serious soft-tissue injury Favoured for chronic injuries that have stopped responding to physio Sold pre-blended with BPC-157 as a “Wolverine stack”, and in wider blends with GHK and thymosin-α1
Route	Subcutaneous injection; oral and capsule forms are used for gut complaints; also sold as a ready-made intranasal spray	Subcutaneous injection, from reconstituted lyophilised powder; also sold as a ready-made intranasal spray

Rows describing reported use say what people do, not what has been shown to work. Evidence strength is graded the same way across the whole library, so the two columns are directly comparable.

Read the full entries

BPC-157 → Thymosin-β4 → Open this in the compare tool →

Other comparisons

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Comparing two compounds is not a suggestion to take either one. Talk to a licensed clinician before acting on anything you read here. How to read these entries.